This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignee: Immunocore Limited. Active years: 2023.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2023
Title: Ruth Martinez Hague: Innovator in Cancer Immunotherapy
Introduction
Ruth Martinez Hague is a prominent inventor based in Abingdon, GB. She has made significant contributions to the field of cancer immunotherapy through her innovative research and development of T cell receptors.
Latest Patents
Ruth holds a patent for T cell receptors specific for the NY-ESO-1 tumor antigen-HLA-A*02 complex. This invention relates to T cell receptors (TCRs) that bind the HLA-A*02 restricted peptide SLLMWITQC derived from the cancer antigen NY-ESO-1. The TCRs may include mutations within the alpha and/or beta variable domains relative to a native NY-ESO-1 TCR. These TCRs are particularly suitable for use as novel immunotherapeutic reagents for the treatment of malignant diseases.
Career Highlights
Ruth is associated with Immunocore Limited, a company focused on developing innovative therapies for cancer treatment. Her work has been instrumental in advancing the understanding and application of T cell receptors in immunotherapy.
Collaborations
Ruth collaborates with notable colleagues, including Fiona Chester and Andrew Alexander Knox, who contribute to her research efforts and the development of new therapeutic strategies.
Conclusion
Ruth Martinez Hague's work in developing T cell receptors for cancer treatment exemplifies her commitment to advancing medical science. Her contributions are paving the way for innovative immunotherapeutic approaches that could significantly impact cancer treatment.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile